Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders
References (29)
- et al.
Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates
Anal. Biochem.
(1980) - et al.
Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA)
J. Biol. Chem.
(1991) - et al.
Studies on the ability of 65-kDa and 92-kDa tumor cell gelatinases to degrade type IV collagen
J. Biol. Chem.
(1990) - et al.
Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis
J. Neuroimmunol.
(1991) - et al.
Human hepatoma cells produced an 85 kDa gelatinase regulated by phorbol 12-myristate 13-acetate
Biochim. Biophys. Acta
(1990) Metalloproteinases and their inhibitors in matrix remodeling
Trends Genet.
(1990)- et al.
Natural human monocyte gelatinase and its inhibitor
FEBS Lett.
(1991) - et al.
Interleukin 6 enhances the production of tissue inhibitor of metalloproteinase (TIMP) but not that of matric metallopreteinase by human fibroblasts
Biochem. Biophys. Res. Commun.
(1990) - et al.
Degradation of myelin basic protein by cerebrospinal fluid: preservation of antigenic determinants under physiological conditions
Ann. Neurol.
(1979) - et al.
Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis
Nature
(1980)
Degradation of basic protein in myelin by neutral proteases secreted by stimulated macrophages: A possible mechanism of inflammatory demyelination
Proteolytic enzyme activity of blood leukocytes and cerebrospinal fluid in multiple sclerosis
Ann. Neurol.
Production of B cell stimulatory factor-2 and interferon-gamma in the central nervous system during viral meningitis and encephalitis
J. Exp. Med.
Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis
Eur. J. Immunol.
Cited by (286)
Oxysterols and multiple sclerosis: Physiopathology, evolutive biomarkers and therapeutic strategy
2021, Journal of Steroid Biochemistry and Molecular BiologyThe multifaceted role of metalloproteinases in physiological and pathological conditions in embryonic and adult brains
2017, Progress in NeurobiologyMarine pharmacology: therapeutic targeting of matrix metalloproteinases in neuroinflammation
2017, Drug Discovery TodayCitation Excerpt :Although several studies demonstrated that alteration of various MMPs contributes to the development of MS, a convergence of data indicate MMP-9 as the key factor involved in different steps of MS pathogenesis (Fig. 3b). During the acute MS phase, MMP-9 levels are elevated in the cerebrospinal fluid (CSF) and are related to magnetic resonance imaging (MRI) activity [34,35]. Liuzzi et al. [36] demonstrated the intrathecal synthesis of MMP-9 and found a significant inverse correlation between MMP-9 and its endogenous inhibitor TIMP-1, indicating that in MS patients the increase in MMP-9 and the decrease in TIMP-1 serum levels could contribute to BBB disruption and T lymphocyte entry into the CNS.
Multiple sclerosis: Association of gelatinase B/matrix metalloproteinase-9 with risk and clinical course the disease
2017, Multiple Sclerosis and Related DisordersCitation Excerpt :Despite controversial results (La Russa et al., 2010; Mirowska-Guzel et al., 2009), it is generally accepted that the −1562 C/T polymorphism has no impact on susceptibility to MS (Nischwitz et al., 2015), but its possible influence on disease course is still largely unknown. At protein level, both gelatinase B/MMP-9 increased concentration (Gijbels et al., 1992; Lee et al., 1999) and activity (Avolio et al., 2003; Liuzzi et al., 2002) in serum and in the cerebrospinal fluid (CSF) of MS patients, compared to controls, have been well established. In fact, this MMP has been suggested as a useful marker for the evaluation of the clinical type, disability and severity of MS (Benesova et al., 2009).